Brief: Cellivery Therapeutics Inc Submits 1St Phase Clinical Trial Plans Of Covid-19 Treatment To Us FDA

Cellivery Therapeutics

13/09/2022 08:07

Sept 13 (Reuters) - Cellivery Therapeutics Inc  268600.KQ :
    * SUBMITS 1ST PHASE CLINICAL TRIAL PLANS OF COVID-19
TREATMENT TO
US FDA

Further company coverage:  268600.KQ 

 (Reporting by Joyce Lee)
 ((JungYoon.Lee@thomsonreuters.com;))